Post-earnings recap
Reported
Wed, Feb 19, 2025
EPS actual
$0.92
EPS est.
$0.55
EPS surprise
+67.27%
1-day move
+1.16%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
BioMarin's strong EPS performance indicates better-than-expected profitability, which likely contributed to the positive stock reaction. However, the lack of revenue data and guidance leaves some uncertainty for investors. The stock's 1.16% increase reflects market approval of the earnings surprise.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.92 | N/A | +67.27% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. They emphasized ongoing efforts to enhance product offerings.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering innovative therapies.